Loading clinical trials...
Loading clinical trials...
Early Prevention Strategies of Severe Proliferative Vitreoretinopathy Base on Precision Diagnosis of Single Cell Sequencing
Study of initiating proliferative vitreoretinopathy (PVR)cell subtype (PVR initiating cells (PVR-IC) in RPE cells of rhegmatogenous retinal detachment (RRD) patients; to prove the percentage of PVR-IC decides the risk of serious PVR occurring after surgery; to investigate the safety and efficacy of early local steroids drug intervention in patients with severe postoperative PVR.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Start Date
September 1, 2020
Primary Completion Date
June 30, 2022
Completion Date
December 31, 2022
Last Updated
August 20, 2020
60
ESTIMATED participants
RPE cell collection and single cell heterogeneity study
DIAGNOSTIC_TEST
Postoperative intervention
PROCEDURE
Conventional Surgery for Retinal Detachment
PROCEDURE
Lead Sponsor
Shanghai 10th People's Hospital
NCT05331664
NCT06541574
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07054281